解放军医学院学报2017，Vol.38Issue(3)：274-276,3.DOI:10.3969/j.issn.2095-5227.2017.03.024
单倍体相合造血干细胞移植治疗重型再生障碍性贫血进展
Advances in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia
摘要
Abstract
Matched sibling donor (MSD) or matched unrelated donor (MUD) hematopoietic stem cell transplantation is the front-line therapy for severe aplastic anemia. When MSD or MUD is not available, then intensive immunosuppressive therapy (IST) is indicated. However, IST has a high relapse rate due to lack of response. Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) has been developing so rapidly that they could now replace the transplantation from identical siblings with similar efficacy. The application of Haplo-HSCT terminate the era of donor shortage and bring benefit to the patients. This review will focus on the progress of the therapeutic effect of Haplo-HSCT in the treatment of SAA.关键词
重型再生障碍性贫血/造血干细胞移植/单倍体Key words
severe aplastic anemia/hematopoietic stem cell transplantation/haploid分类
医药卫生引用本文复制引用
王丽,吴亚妹,曹永彬,李晓红,徐丽昕,汪海涛,高亚会,吴晓雄..单倍体相合造血干细胞移植治疗重型再生障碍性贫血进展[J].解放军医学院学报,2017,38(3):274-276,3.基金项目
部委级资助项目 （）
全军医学科技青年培育项目 (16QNO138) Supported by the Medical Science and Technique Training Foundation for Youths of the Chinese People's Liberation Army (16QNO138) （16QNO138）
